New PET scan for early lung cancer detection
Positron-Emission Tomography Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
This study tests a new type of PET scan using a special tracer to see if it can help find early lung cancer in people.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05558904 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the safety and effectiveness of a novel PET scan using a new glucose tracer, Me-4FDG, designed to detect lung adenocarcinoma at an early stage. Participants will receive the tracer intravenously and undergo a PET/CT scan to assess glucose uptake in potential tumor cells. The study aims to correlate the results of the PET scan with histopathological features of lung cancer. Follow-up will occur seven days after the procedure to monitor safety and efficacy.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with lung nodules of 1 cm or larger, either confirmed as lung adenocarcinoma or classified as benign according to specific guidelines.
Not a fit: Patients who are pregnant, have diabetes, or are currently taking SGLT2 inhibitors or metformin may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnosis of lung cancer, improving treatment outcomes.
How similar studies have performed: Other studies using PET imaging for cancer detection have shown promise, but the use of Me-4FDG specifically for lung cancer detection is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Lung nodule \>= 1 cm visualized by CT imaging * CANCER ARM: Pathologically confirmed lung adenocarcinoma. For patients who are surgical candidates, the pathologic report on the surgical specimen will confirm the diagnosis. For patients who are not surgical candidates, the enrollment will be contingent upon a pathologic diagnosis of lung cancer obtained by needle biopsy * BENIGN ARM: Lung nodules considered to be clinically benign, according to the Guidelines for Management of Incidental Pulmonary Nodules from the Fleischner Society. Will consider "benign" the nodules with a lung-RADS score of 1-3 Exclusion Criteria: * Pregnancy * Diagnosis of diabetes * Current treatment with SGLT2 inhibitors or metformin
Where this trial is running
Los Angeles, California
- Yesenia Calzada — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Claudio Scafoglio, MD, PhD — UCLA / Jonsson Comprehensive Cancer Center
- Study coordinator: Yesenia Calzada
- Email: YCalzada@mednet.ucla.edu
- Phone: 424.946.5026
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.